Chimeric antigen receptor T-cell therapy (CAR T-cell therapy) is a type of adoptive cell transfer or immunotherapy that uses genetically modified T-cells to find and kill cancer cells. In CAR T-cell therapies, T cells are taken from the patient’s blood and are changed in the lab by adding a gene for a man-made receptor (called a chimeric antigen receptor or CAR). This helps them better identify specific cancer cell antigens. The CAR T cells are then given back to the patient. 在 2021, the global CAR T-cell therapy market stood at USD 1,532 百万. 复合年增长率为 36.2% 从 2022 到 2028, 预计价值将达到 ~USD 13,317 百万 2028, 根据 Gen Consulting 公司的一份新报告.

该报告提供了有关当前全球市场情况的深入分析和见解, latest trends and drivers into global CAR T-cell therapy market. 它提供了对市场规模等各种细节的独家见解, 主要趋势, 竞争格局, 增长率和细分市场. This study also provides an analysis of the impact of the COVID-19 crisis on the CAR T-cell therapy industry.

该行业报告提供了全球市场的市场估计和预测, 接下来是对产品的详细分析, target antigen, 和地区. The global market for CAR T-cell therapy can be segmented by product: tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), 其他的. The Yescarta segment is estimated to account for the largest share of the global CAR T-cell therapy market. CAR T-cell therapy market is further segmented by target antigen: CD19/CD22, BCMA (B-cell maturation antigen), 其他的. 根据地区, the CAR T-cell therapy market is segmented into: 亚太地区, 欧洲, 北美, 世界其他地区 (排). 全球范围, North America made up the largest share of the CAR T-cell therapy market.

副产品:
– tisagenlecleucel (Kymriah)
– axicabtagene ciloleucel (Yescarta)
– brexucabtagene autoleucel (Tecartus)
– 其他的

By target antigen:
– CD19/CD22
– BCMA (B-cell maturation antigen)
– 其他的

按地区:
– 亚太地区
– 欧洲
– 北美
– 世界其他地区 (排)

The market research report covers the analysis of key stake holders of the global CAR T-cell therapy market. Some of the leading players profiled in the report include AbbVie Inc., Amgen Inc., 阿斯利康公司, Autolus Therapeutics plc, Bellicum Pharmaceuticals, 公司, bluebird bio, 公司, 百时美施贵宝公司, CARsgen Therapeutics Co., 有限公司, Cartesian Therapeutics, 公司, Cellectis S.A., Celyad Oncology S.A., Editas Medicine, 公司, Fortress Biotech Inc., Gilead Sciences, 公司, Janssen Pharmaceuticals, 公司, Legend Biotech Corporation, Mustang Bio, 公司, 诺华国际公司, 辉瑞公司, PureTech Health plc, Servier Laboratories Ltd., 武田制药有限公司, 除其他外.
*索取免费样品以获得完整的公司列表

历史 & 预测期
本研究报告对各个细分市场进行了分析 2018 到 2028 考虑到 2021 为基准年.

报告范围
– To analyze and forecast the market size of the global CAR T-cell therapy market.
– To classify and forecast the global CAR T-cell therapy market based on product, target antigen, 地区.
– To identify drivers and challenges for the global CAR T-cell therapy market.
– 检查合并等竞争性发展 & 收购, 协议, 合作与伙伴关系, ETC。, in the global CAR T-cell therapy market.
– To identify and analyze the profile of leading players operating in the global CAR T-cell therapy market.

为什么选择这份报告
– Gain a reliable outlook of the global CAR T-cell therapy market forecasts from 2022 到 2028 跨场景.
– 确定投资的增长领域.
– 通过公司简介和市场数据领先于竞争对手.
– Excel 格式的跨场景分析易用性的市场预估.
– 三个月的战略咨询和研究支持.
– 为单用户许可证提供打印验证.